- Home
- TTOO vs BOLD Comparison
TTOO vs BOLD Comparison
Compare TTOO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTOO
- BOLD
- Stock Information
- Founded
- TTOO 2006
- BOLD 2018
- Country
- TTOO United States
- BOLD United States
- Employees
- TTOO N/A
- BOLD N/A
- Industry
- TTOO Medical/Dental Instruments
- BOLD
- Sector
- TTOO Health Care
- BOLD
- Exchange
- TTOO Nasdaq
- BOLD Nasdaq
- Market Cap
- TTOO 36.4M
- BOLD 81.0M
- IPO Year
- TTOO 2014
- BOLD 2024
- Fundamental
- Price
- TTOO $0.97
- BOLD $2.95
- Analyst Decision
- TTOO Hold
- BOLD Strong Buy
- Analyst Count
- TTOO 1
- BOLD 3
- Target Price
- TTOO $5.00
- BOLD $23.00
- AVG Volume (30 Days)
- TTOO 710.5K
- BOLD 57.8K
- Earning Date
- TTOO 11-13-2024
- BOLD 11-11-2024
- Dividend Yield
- TTOO N/A
- BOLD N/A
- EPS Growth
- TTOO N/A
- BOLD N/A
- EPS
- TTOO N/A
- BOLD N/A
- Revenue
- TTOO $7,164,000.00
- BOLD N/A
- Revenue This Year
- TTOO $50.31
- BOLD N/A
- Revenue Next Year
- TTOO $117.92
- BOLD N/A
- P/E Ratio
- TTOO N/A
- BOLD N/A
- Revenue Growth
- TTOO N/A
- BOLD N/A
- 52 Week Low
- TTOO $0.90
- BOLD $2.82
- 52 Week High
- TTOO $8.38
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- TTOO 18.34
- BOLD N/A
- Support Level
- TTOO $0.90
- BOLD N/A
- Resistance Level
- TTOO $1.86
- BOLD N/A
- Average True Range (ATR)
- TTOO 0.15
- BOLD 0.00
- MACD
- TTOO -0.00
- BOLD 0.00
- Stochastic Oscillator
- TTOO 5.72
- BOLD 0.00
About TTOO T2 Biosystems Inc.
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.